Cardiovascular effects of the 3 phosphodiesterase-5 inhibitors approved for the treatment of erectile dysfunction

Circulation

Volumn 110, Issue 19, 2004, Pages 3149-3155

  Kloner, Robert A ^a,b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b GOOD SAMARITAN HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; CYCLIC GMP; GLYCERYL TRINITRATE; GUANYLATE CYCLASE; ISOSORBIDE DINITRATE; ISOSORBIDE MONONITRATE; NITRATE; NITRIC OXIDE DONOR; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; SILDENAFIL; TADALAFIL; VARDENAFIL;

ATHEROSCLEROSIS; BACKACHE; BLOOD PRESSURE; CARDIOVASCULAR EFFECT; CORONARY ARTERY DISEASE; DEATH; DIABETES MELLITUS; DIARRHEA; DIZZINESS; DRUG HALF LIFE; DYSPEPSIA; ERECTILE DYSFUNCTION; EXERCISE; FLU LIKE SYNDROME; FLUSHING; FOOD AND DRUG ADMINISTRATION; HEADACHE; HEART INFARCTION; HEART RATE; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; LIMB PAIN; LUNG VASCULAR RESISTANCE; MYALGIA; NAUSEA; NOSE CONGESTION; PRIORITY JOURNAL; QT INTERVAL; REVIEW; RHINITIS; RISK FACTOR; SINUSITIS; SMOKING; URINARY TRACT INFECTION; VASCULAR DISEASE; VASODILATATION; VISUAL DISORDER;

3',5'-CYCLIC-GMP PHOSPHODIESTERASE; ADRENERGIC ALPHA-ANTAGONISTS; ARTERIOSCLEROSIS; BLOOD PRESSURE; CARBOLINES; CORONARY DISEASE; CYCLIC GMP; DRUG INTERACTIONS; ENDOTHELIUM, VASCULAR; HEART RATE; HUMANS; HYPOTENSION; IMIDAZOLES; IMPOTENCE; ISOSORBIDE DINITRATE; MALE; MOLECULAR STRUCTURE; MYOCARDIAL INFARCTION; NITRIC OXIDE DONORS; NITROGLYCERIN; PHOSPHODIESTERASE INHIBITORS; PHOSPHORIC DIESTER HYDROLASES; PIPERAZINES; RANDOMIZED CONTROLLED TRIALS; SULFONES; TRIAZINES; VASODILATION; VASODILATOR AGENTS;

EID: 8544233528     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000146906.42375.D3     Document Type: Review

References (57)

1. Goldstein I, Lue TF, Padma-Nathan H, et al. Oral sildenafil in the treatment of erectile dysfunction. N Engl J Med. 1998;338:1397-1404.
2. Padma-Nathan H. Sildenafil citrate (Viagra) and erectile dysfunction: a comprehensive four year update on efficacy, safety, and management options. Urology. 2002;60(suppl):1-90.
3. Hellstrom WJG, Gittleman M, Karlin G, et al. Vardenafil for treatment of men with erectile dysfunction: efficacy and safety in a randomized double-blind, placebo-controlled trial. J Androl. 2002;23:763-771.
4. Brock GB, McMahon CG, Chen KK, et al. Efficacy and safety of tadalafil for the treatment of erectile dysfunction: results of an integrated analysis. J Urol. 2001;168:1322-1336.
5. Gresser U, Gleiter OH. Erectile dysfunction: comparison of efficacy and side effects of the PDE5 inhibitors sildenafil, vardenafil and tadalafil. Eur J Med Res. 2002;7:435-446.
6. Kloner RA, Jarow JP. Erectile dysfunction and sildenafil citrate and cardiologists. Am J Cardiol. 1999;83:576-582.
7. Feldman HA, Goldstein I, Hatzichristou DG, et al. Impotence and its medical and psychological correlates: results of the Massachusetts Male Aging Study. J Urol. 1994;151:54-61.
8. Feldman HA, Johannes CB Derby CA, et al. Erectile dysfunction and coronary risk factors: prospective results from the Massachusetts Male Aging Study. Prev Med. 2000;30:328-338.
9. Azadzoi KM, Siroky MB, Goldstein I. Study of etiologic relationship of arterial atherosclerosis to corporal veno-occlusive dysfunction in the rabbit. J Urol. 1996;155:1795-1800.
10. Kaiser DR, Billups K, Mason C, et al. Impaired brachial artery endothelium- dependent and -independent vasodilation in men with erectile dysfunction and no other clinical cardiovascular disease. J Am Coll Cardiol. 2004;43:179-184.
11. Kloner RA, Mullin SH, Shook T, et al. Erectile dysfunction in the cardiac patient: how common and should we treat? J Urol. 2003;170:S46-S50.
12. Jackson G, Benjamin N, Jackson N, et al. Effects of sildenafil citrate on human hemodynamics. Am J Cardiol. 1999;83:13C-20C.
13. Zusman RM, Morales A, Glasser DB, et al. Overall cardiovascular profile of sildenafil citrate. Am J Cardiol. 1999;83:35C-44C.
14. Hermann HC, Chang G, Klugherz BD, et al. Hemodynamic effects of sildenafil in men with severe coronary artery disease. N Engl J Med. 2000;342:1622-1626.
15. Kloner RA. Sex and the patient with cardiovascular risk factors: focus on sildenafil. Am J Med. 2000;109 (suppl 9A):13S-21S.
16. Zhao L, Mason NA, Morrell N, et al. Sildenafil inhibits hypoxia-induced pulmonary hypertension. Circulation. 2001;104:424-428.
17. Prasad S, Wilkinson J, Gatzoulis MA. Sildenafil in primary pulmonary hypertension. N Engl J Med. 2000;343:1342.
18. Wilkens H, Guth A, Konig J, et al. Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension. Circulation. 2001;104:1218-1222.
19. Product monograph for Levitra (vardenafil HCL). Bayer Health Care, Glaxo SmithKline; 2003.
20. Emmick JT, Stuewe SR, Mitchell M. Overview of the cardiovascular effects of tadalafil. Eur Heart J Suppl. 2002;4(suppl H):H32-H47.
21. Kloner RA, Mitchell M, Emmick JT. Cardiovascular effects of tadalafil. Am J Cardiol. 2003;92(suppl):37M-46M.
22. Cheitlin MD, Hutter AM Jr, Brindis RG, et al. ACC/AHA expert consensus document use of sildenafil (Viagra) in patients with cardiovascular disease. American College of Cardiology/American Heart Association. J Am Coll Cardiol 1999;33:273-282.
23. DeBusk R, Drory Y, Goldstein I, et al. Management of sexual dysfunction in patients with cardiovascular disease: recommendations of the Princeton Consensus Panel. Am J Cardiol 2000;86:175-181.
24. Rosen RC, Kostis JB. Overview of phosphodiesterase 5 inhibition in erectile dysfunction. Am J Cardiol. 2003;92 (suppl):9M-18M.
25. Webb DJ, Freestone S, Allen MJ, et al. Sildenafil citrate and blood-pressure-lowering drugs; results of drug interaction studies with an organic nitrate and a calcium antagonist. Am J Cardiol. 1999;83: 21C-28C.
26. Webb DJ, Muirhead GJ, Wolff M, et al. Sildenafil citrate potentiates the hypotensive effects of nitric oxide donor drugs in male patients with stable angina. J Am Coll Cardiol. 2000;36:25-31.
27. Oliver JJ, Bell K, Leekie SM, et al. Interaction between glyceryl trinitrate and sildenafil citrate (Viagra) may last less than four hours. Int J Impot Res. 2002;14(suppl 3):S22-S28.
28. Kloner RA, Hutter AM, Emmick JT, et al. Time course of the interaction between tadalafil and nitrates. J Am Coll Cardiol. 2003;42:1855-1860.
29. DeBusk RF. Sexual activity in patients with angina. JAMA. 2003;290: 3129-3132.
30. Zusman RM, Prisant LM, Brown MJ. Effect of sildenafil citrate on blood pressure and heart rate in men with erectile dysfunction taking concomitant antihypertensive medication. Sildenafil Study Group. J Hypertens. 2000;18:1865-1869.
31. Kloner RA, Brown M, Prisant LM, et al for the Sildenafil Study Group. Effect of sildenafil in patients with erectile dysfunction taking antihypertensive therapy. Am J Hypertens. 2001;14:70-73.
32. Pickering TG, Mancia G, Glasser DB, et al. Safety of Viagra (sildenafil citrate) in men with erectile dysfunction and arterial hypertension who are taking multiple antihypertensive treatments. Am J Hypertens. 2002; 15(suppl 1):A55-A56.
33. Kloner RA, Mohan P, Segerson T, et al. Cardiovascular safety of vardenafil in patients receiving antihypertensive medications: a post-hoc analysis of five placebo-controlled trials. J Am Coll Cardiol. 2003;41(suppl A):276A-277A.
34. Padma-Nathan H, Porst H, Eardley I, et al. Efficacy and safety of vardenafil, a selective phosphodiesterase 5 inhibitor, in men with erectile dysfunction on antihypertensive therapy. Presented at the American Society of Hypertension 17th Annual Scientific Meeting. New York, NY, 2002.
35. Rohde G, Jordan P. Influence of vardenafil on blood pressure and pharmacokinetics in hypertensive patients on nifedipine therapy. Pharmacotherapy. 2002;22:418. Abstract.
36. Kloner RA, Mitchell M, Emmick JT. Cardiovascular effects of tadalafil in patients on common antihypertensive therapies. Am J Cardiol. 2003; 92(suppl):47M-57M.
37. Sildenafil prescribing information. New York, NY: Pfizer; 2004.
38. Auerbach S, Gittelman M, Mazzu A, et al. Coadministered vardenafil (for erectile dysfunction) and tamsulosin do not induce hypotension in patients with benign prostatic hypertrophy. Am J Hypertens. 2004; 17:16A. Abstract.
39. Kloner RA, Jackson G, Emmick JT, et al. Interaction between the phosphodiesterase 5 inhibitor, tadalafil, and the two α-blockers doxazosin and tamsulosin in healthy normotensive men. J Urol. In press.
40. Data on file. Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee: LEVITRA tablets. Available at http:// www.fda.gov/ohrms/ dockets/ac/03/slides/3956S1-03-Bayer.ppt. Accessed September 5, 2003.
41. Cialis (tadalafil) prescribing information. Indianapolis, Ind/Bothell, Wash: Lilly ICOS LLC; 2003.
42. Reffelmann T, Kloner RA. Effects of sildenafil on myocardial infarct size, microvascular function, and acute ischemic ventricular dilatation. Cardiovasc Res. 2003;59:441-449.
43. Fox KM, Thadani U, Ma PTS, et al, on behalf of the CAESAR 1 (Clinical American and European Studies of Angina And Revascularization) Investigators. Sildenafil citrate does not reduce exercise tolerance in men with erectile dysfunction and chronic stable angina. Eur Heart J. 2003;24: 2206-2212.
44. Arruda-Olson AM, Mahoney DW, Nehra A, et al. Cardiovascular effects of sildenafil during exercise in men with known or probable coronary artery disease: a randomized crossover trial. JAMA. 2002;287:719-725.
45. Thadani U, Smith W, Nash S, et al. The effect of vardenafil, a potent and highly selective phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction on the cardiovascular response to exercise in patients with coronary artery disease. J Am Coll Cardiol. 2002;40:2006-2012.
46. Patterson D, MacDonald TM, Effron MB, et al. Tadalafil does not affect time to ischemia during exercise stress testing in patients with coronary artery disease. Circulation. 2002;(suppl II):106:II-330.
47. Halcox JPJ, Nour KRA, Zalos G, et al. The effect of sildenafil on human vascular function, platelet activation, and myocardial ischemia. J Am Coll Cardiol. 2002;40:1232-1240.
48. Muller JE, Mittleman A, Maclure M, et al. Triggering myocardial infarction by sexual activity: low absolute risk and prevention by regular physical exertion. JAMA. 1996;275:1405-1409.
49. Kloner RA. Introduction: erectile dysfunction and cardiovascular risk factors. Am J Cardiol. 2003;92(suppl):1M-2M.
50. Morales A, Gingell C, Collins M, et al. Clinical safety of oral sildenafil citrate (Viagra) in the treatment of ED. Int J Impot Res. 1998;10:69-74.
51. Conti CR, Pepine CJ, Sweeney M. Efficacy and safety of sildenafil citrate in the treatment of ED in patients with ischemic heart disease. Am J Cardiol. 1999;83(suppl 5A):29C-34C.
52. Wysowski DK, Farinas E, Swartz L. Comparison of reported and expected deaths in sildenafil (Viagra) users. Am J Cardiol. 2002;89: 1331-1334.
53. Mittleman MA, Glasser DB, Orazem J. Clinical trials of sildenafil citrate (Viagra) demonstrate no increase in risk of myocardial infarction and cardiovascular death compared with placebo. Int J Clin Pract. 2003;57: 597-600.
54. Shakir SAW, Wilton LV, Boshier A, et al. Cardiovascular events in users of sildenafil: results from first phase of prescription event monitoring in England. BMJ. 2001;322:651-652.
55. Kloner RA. Cardiovascular risk and sildenafil. Am J Cardiol. 2000; 86(suppl):57F-61F.
56. Kloner RA, Mohan P, Norenberg C, et al. Cardiovascular safety of vardenafil, a potent, highly selective PDE5 inhibitor in patients with erectile dysfunction: analysis of five controlled clinical trials. Pharmacol Ther. 2002;22:1371.
57. DeBusk RF, Pepine CJ, Glasser DB, et al. Efficacy and safety of sildenafil citrate in men with erectile dysfunction and stable coronary artery disease. Am J Cardiol. 2004;93:147-153.